OverviewSuggest Edit

Athenex is a biopharmaceutical company dedicated to the discovery and commercialization of therapies for the treatment of cancer. It operates medical technology innovation centers and a manufacturing supply chain. The company delivers proprietary medical technologies, including small molecule, biologic, and cellular therapies.
TypePublic
Founded2003
HQBuffalo, NY, US
Websiteathenex.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Dec 2018)575
Job Openings21
Revenue (FY, 2020)$144.4 M(+43%)
Share Price (Apr 2021)$4(-3%)
Cybersecurity ratingAMore

Key People/Management at Athenex

Johnson Y.n. Lau

Johnson Y.n. Lau

Chief Executive Officer and Board Chairman, Director
Rudolf Kwan

Rudolf Kwan

Chief Medical Officer
Kim Campbell

Kim Campbell

Lead Independent Director
Jeffrey Yordon

Jeffrey Yordon

Chief Operating Officer President – Athenex Pharmaceutical Division
Simon Pedder

Simon Pedder

Chief Business and Strategy Officer, Proprietary Products
Stephanie Davis

Stephanie Davis

Director
Show more

Athenex Office Locations

Athenex has offices in Buffalo, Clarence, Cranford, Houston and in 3 other locations
Buffalo, NY, US (HQ)
Conventus, 1001 Main St #600
Clarence, NY, US
11342 Main St
Cranford, NJ, US
20 Commerce Dr #100
Houston, TX, US
6200 Savoy Dr #1200
Schaumburg, IL, US
10 N Martingale Rd #230
Guatemala, GT
4A Avenida 14-21
Show all (11)

Athenex Financials and Metrics

Athenex Revenue

Embed Graph
View revenue for all periods
Athenex's revenue was reported to be $144.39 m in FY, 2020
USD

Revenue (FY, 2020)

144.4m

Gross profit (FY, 2020)

49.0m

Gross profit margin (FY, 2020), %

34%

Net income (FY, 2020)

(148.4m)

EBIT (FY, 2020)

(123.7m)

Market capitalization (16-Apr-2021)

371.0m

Closing stock price (16-Apr-2021)

4.0

Cash (31-Dec-2020)

69.6m

EV

313.0m
Athenex's current market capitalization is $371 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

38.0m89.1m101.2m144.4m

Cost of goods sold

25.1m47.0m69.6m95.4m

Gross profit

12.9m42.1m31.6m49.0m

Gross profit Margin, %

34%47%31%34%
Quarterly
USDQ2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

4.6m14.0m37.8m11.6m18.4m25.3m22.2m19.4m46.9m40.2m35.5m

Cost of goods sold

4.1m8.1m11.3m9.4m12.0m19.9m16.9m17.1m19.6m33.0m24.5m

Gross profit

458.0k5.9m26.5m2.1m6.5m5.4m5.3m2.3m27.4m7.2m11.0m

Gross profit Margin, %

10%42%70%18%35%21%24%12%58%18%31%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

39.3m49.8m127.7m69.6m

Accounts Receivable

8.5m13.0m16.7m23.6m

Prepaid Expenses

7.7m21.7m20.8m14.8m

Inventories

16.6m28.8m32.6m28.8m
Quarterly
USDQ2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

55.2m19.3m39.2m14.1m51.1m71.0m96.7m61.5m72.0m105.9m143.6m

Accounts Receivable

3.8m6.5m7.8m5.1m7.1m20.6m9.6m17.2m51.4m38.6m43.0m

Prepaid Expenses

4.0m5.9m7.2m12.0m14.0m33.6m47.0m38.7m17.0m19.5m9.5m

Inventories

9.3m11.6m18.6m21.8m25.2m25.2m27.2m28.5m35.7m31.1m29.6m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(131.4m)(128.7m)(125.5m)(148.4m)

Depreciation and Amortization

3.7m3.3m3.8m4.5m

Inventories

(12.3m)(12.2m)(3.8m)3.8m

Accounts Payable

18.8m3.5m19.3m(13.1m)
Quarterly
USDQ2, 2017

Financial Leverage

1.3 x
Show all financial metrics

Athenex Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Athenex Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Athenex Online and Social Media Presence

Embed Graph

Athenex News and Updates

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Athenex, Inc., of Class Action Lawsuit and Upcoming Deadline - ATNX

NEW YORK, April 13, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or the "Company") (NASDAQ: ATNX) and certain of its officers. The class action, filed in the United States District Court for the Western District...

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Velodyne Lidar, Renewable Energy Group, Athenex, and Ontrak and Encourages Investors to Contact the Firm

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Velodyne Lidar, Inc. (NASDAQ: VLDR), Renewable Energy Group, Inc. (NASDAQ: REGI),…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Athenex, Inc., of Class Action Lawsuit and Upcoming Deadline - ATNX

NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or the "Company") (NASDAQ: ATNX) and certain of its officers. The class action, filed in the United States District Court for the Western District of...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Athenex (ATNX) Investors of Securities Fraud Lawsuit and Application Deadline, Encourages Investors with Losses to Contact Their Attorneys

SAN FRANCISCO, April 05, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now.

Pomerantz Law Firm Announces the Filing of a Class Action against Athenex, Inc., and Certain Officers - ATNX

NEW YORK, March 23, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or the "Company") (NASDAQ: ATNX) and certain of its officers. The class action, filed in the United States District Court for the Western District...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Athenex (ATNX) Investors of Securities Class Action and Encourages Investors with Losses to Contact Its Attorneys

SAN FRANCISCO, March 22, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now.
Show more

Athenex Blogs

CEO Dr. Johnson Lau Recuperating from COVID at Home

BUFFALO, N.Y. , Jan. 25, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its CEO and Board Chairman,

CEO Dr. Johnson Lau Contracts COVID-19

BUFFALO, N.Y. , Jan. 08, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr.

Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide

Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide Content Import Wed, 12/02/2020 - 08:00 Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide…

Athenex, Inc. Reports Third Quarter Ended September 30, 2020 Financial Results and Provides Corporate Update

FDA accepted and granted priority review of NDA for Oral Paclitaxel in metastatic breast cancer PDUFA dates for tirbanibulin ointment and Oral Paclitaxel set for December 30, 2020 and February 28, 2021 , respectively Four abstracts featuring Oral Paclitaxel accepted for presentation at San Antonio

Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020

Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020 Content Import Thu, 10/22/2020 - 07:01 Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020 October 22, 2020 This release is a backfill from a News Wire …

Athenex Frequently Asked Questions

  • When was Athenex founded?

    Athenex was founded in 2003.

  • Who are Athenex key executives?

    Athenex's key executives are Johnson Y.n. Lau, Rudolf Kwan and Kim Campbell.

  • How many employees does Athenex have?

    Athenex has 575 employees.

  • What is Athenex revenue?

    Latest Athenex annual revenue is $144.4 m.

  • What is Athenex revenue per employee?

    Latest Athenex revenue per employee is $251.1 k.

  • Who are Athenex competitors?

    Competitors of Athenex include Telix Pharmaceuticals, Mentrik Biotech and Precision Medicines.

  • Where is Athenex headquarters?

    Athenex headquarters is located at Conventus, 1001 Main St #600, Buffalo.

  • Where are Athenex offices?

    Athenex has offices in Buffalo, Clarence, Cranford, Houston and in 3 other locations.

  • How many offices does Athenex have?

    Athenex has 11 offices.